Skip to content
Investing

Rheinmetall Shares Slump as Delayed Army Contracts Force a Guidance Cut

Rheinmetall shares fell as much as 16 percent after the defence group cut its 2026 sales forecast to about €13.2 billion, blaming delays to German army contracts and ammunition tests.

The entrance to Rheinmetall's Waffe Munition weapons and ammunition plant in Unterlüß, Lower Saxony, with the Rheinmetall sign, parked cars and factory buildings.
Photo: Hajotthu / Wikimedia Commons, CC BY-SA 3.0

Rheinmetall shares fell as much as 16 percent on Thursday after Germany's largest defence company cut its 2026 sales and margin targets. The group blamed delays to a major contract for the German army and to acceptance tests for artillery ammunition, even as nine-month sales rose 38 percent.

The Düsseldorf-based group now expects 2026 sales of about €13.2 billion, below its previous range of €13.7 billion to €14.2 billion. It lowered its operating margin target to about 18.5 percent from about 19 percent. It was the company's second cut to its outlook since August.

The wider market was calmer: the Stoxx 600 was up about 0.5 percent shortly after the open and Germany's DAX was marginally higher.

Two Delays Behind the Cut

Rheinmetall pointed to two problems, both about timing rather than lost business.

The first is Arminius, a project for the German armed forces linked to the Boxer armoured vehicle. The company said the contract is in the final phase of negotiations and cannot be commissioned until next year, which pushes the related sales out of 2026.

The second is lot acceptance testing for artillery ammunition, the checks a customer runs before taking delivery of a batch of shells. Delays in those tests shift revenue from one period into the next.

2026 outlook, before and after

  • €13.2bn sales guidance, down from €13.7bn to €14.2bn
  • 18.5% operating margin target, down from about 19%
  • 16% maximum share price fall on Thursday
A German Army soldier handles racks of Rheinmetall DM125 155mm artillery shells during the Dynamic Front 25 exercise.
A German Army soldier handles racks of Rheinmetall DM125 155mm artillery shells during the Dynamic Front 25 exercise. Photo: Capt. Thomas McCarty, U.S. Army / Wikimedia Commons, public domain

Strong Growth, Weak Cash

The nine-month figures themselves were strong. Sales rose 38 percent to €8,376 million from €6,057 million a year earlier. The operating result climbed by €544 million to €1,339 million, lifting the margin to 16.0 percent from 13.1 percent.

Orders kept flowing. The backlog reached €78.0 billion at the end of September, up from €56.7 billion a year earlier, and the company's Nomination measure of new orders rose 19 percent to €19.1 billion. Vehicle Systems orders included a second batch of 200 Puma infantry fighting vehicles and 298 Lynx vehicles for Romania, financed under the EU's SAFE defence programme.

Cash was the weak point. Operating free cash flow for the nine months was minus €1,698 million, compared with minus €798 million a year earlier. Rheinmetall attributed the outflow to inventory build-up and higher working capital, and noted that the prior-year period had benefited from large customer advance payments.

Nine months to 30 September20252026
Sales€6,057m€8,376m
Operating result€795m€1,339m
Operating margin13.1%16.0%
Operating free cash flow-€798m-€1,698m
Backlog€56.7bn€78.0bn

Where the Growth Came From

Air Defence was the fastest-growing division, with sales up 63 percent to €731 million. Weapon and Ammunition sales rose 34 percent to €2,705 million at a 23.4 percent margin, the highest in the group. Vehicle Systems grew 20 percent to €3,898 million, and Digital Systems 29 percent to €1,328 million.

Naval Systems appeared as a separate division for the first time, with €679 million of sales over the seven months since its acquisition at the end of February. Chief executive Armin Papperger said: "We are achieving very strong growth coupled with high profitability." The company also said new plants have started production in the UK and in Albacete, Spain.

The Timing Risk in Europe's Rearmament Trade

For investors, the cut shows a risk that sits beneath the long-term case for European defence stocks. Demand is not the issue: the backlog is close to six times this year's expected sales. The problem is when that work turns into revenue, and that depends on government procurement timetables, contract negotiations and testing schedules that companies do not control.

Rheinmetall still expects its operating result to improve this year, though it gave no figure. A second downgrade in three months raises the question of how reliable near-term targets are, even with the order book at a record. The next test is whether the delayed Arminius contract is commissioned next year, as the company now expects, and whether the ammunition that slipped out of this year's tests is delivered on time.

Sources

Related stories

Investing

Hensoldt Raises Its 2026 Guidance and Sets a €10bn Revenue Goal for 2035

Hensoldt lifted its 2026 guidance after a 77% jump in nine-month orders, then set a first €10bn revenue goal for 2035 at its capital markets day, a week after Rheinmetall cut its…

Markets

Rheinmetall Rebounds 16% in a Week as Morgan Stanley Flags a Year-End Order Wave

Rheinmetall shares rose 6.3% on Friday to €1,090.20, a 16.1% rebound over the week, after Morgan Stanley said European defence groups could win a wave of orders before year-end.

Markets

Nasdaq 100 Sinks 5.5% as Chipmakers Suffer Their Longest Losing Streak Since 2008

The Nasdaq 100 fell 5.49% this week as US chip stocks dropped for eight sessions in a row, the longest run since 2008, on AI spending doubts, $110 Brent and 5% yields. AMD lost…

Markets

Bayer Extends Its 15% Rally on a Roundup Jury Win and an Upgraded Outlook

Bayer shares rose about 5% after it raised its 2026 profit outlook on a strong pharma quarter, extending a 15% gain last week that followed a Roundup jury win. Q3 EBITDA beat…

Investing

Aya Gold & Silver Corrects Q3 Cash Costs to $14.28 an Ounce After Silver Double Count

Aya Gold & Silver refiled its Q3 MD&A after silver in transit was deducted twice. Zgounder ounces sold rise to 1,392,478 and cash costs fall to $14.28 from $15.51. Revenue and…

Investing

FDA Rejects Summit's Lung Cancer Drug Ivonescimab Over Phase 3 Survival Miss

The FDA has rejected Summit Therapeutics' lung cancer drug ivonescimab, saying slower tumour growth in the phase 3 HARMONi trial was not enough without a clear gain in survival.

Investing

Red Cat Withdraws Its $150m to $180m 2026 Revenue Target After $11.8m Third Quarter

Red Cat Holdings has withdrawn its $150m to $180m revenue target for 2026 after third-quarter sales of $11.8m, blaming slower defence funding. Its quarterly net loss more than…

Investing

Berkshire Reveals $689m Bending Spoons Stake, Doubles Lennar and Trims Bank of America Again

Berkshire Hathaway's third-quarter 13F shows a new Bending Spoons stake worth $689m, a doubled Lennar holding and 27.5 million more Bank of America shares sold, while Apple stayed…